trending Market Intelligence /marketintelligence/en/news-insights/trending/GDBP_34dywBfOKrrxO-hgw2 content esgSubNav
In This List

Sunovion, Novartis sign license agreement for 3 pulmonary disease drugs

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Sunovion, Novartis sign license agreement for 3 pulmonary disease drugs

Sunovion Pharmaceuticals Inc. and Novartis AG signed an exclusive license agreement for U.S. commercialization rights to three approved chronic obstructive pulmonary disease drugs.

Under the deal, Sunovion will hold exclusive commercialization rights to Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler in the U.S. Novartis will continue to manufacture the three drugs.

The U.S. FDA approved Utibron Neohaler and Seebri Neohaler in 2015. Sunovion plans to bring these two drugs to market in 2017. Arcapta Neohaler was approved in the U.S. in 2011 and arrived in the market in 2012.

Sunovion Pharmaceuticals is a unit of Sumitomo Dainippon Pharma Co. Ltd.